## THE LINES ED STATES PATENT AND TRADEMARK OFFICE

)

In re Application of: Giroir et al.

Serial No: 09/991,603

Filed: November 23, 2001

For: Therapeutic Uses of BPI Protein Products for Human Meningococcemia

Group Art Unit: 1654

Examiner: To be assigned

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail, postage prepaid in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this date:

March 15, 2002

RECEIVED

MAR 2 1 25

lettrey's. Sharp

Registration No. 31,869

TECH CENTER 1600 2900

INFORMATION DISCLOSURE STATEMENT WITH PTO-1449 FORM

Commissioner for Patents Washington, DC 20231

Sivi

In compliance with 37 C.F.R. §1.97 and the duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is bereby submitted by Applicants for consideration in connection with the above-identified patent application. Pursuant to 37 C.F.R. §1.98(1), copies of the documents cited on the PTO-1449 is an are not being provided because they were previously cited by or submitted to the Patent Office in grandparent application U.S. Serial No. 08/927.437 and great-grandparent application U.S. Serial No. 08/644,287, from which priority is claimed under 35 U.S.C. §120. Should the Examiner desire additional copies of the documents, Applicants will provide them upon request.

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This information disclosure statement is submitted before receipt of a first official action on the merits and consequently should be considered by the Patent Office without payment of a fee [see 37 C.F.R. §1.97(b)]. However, should the Patent Office determine that a fee is due for consideration of this information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855.

Respectfully submitted,

## MARSHALL, GERSTEIN & BORUN

By:

Jeffrey S. Sharp

Registration No. 31,869


6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6357

(312) 474-6300

March 15, 2002 Chicago, Illinois



							8
			U.S. PATE	NT DOCUMENTS			<b>-</b>
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
AM	A1	5,578,572	11/26/96	Horwitz et al.	514	12	
<u> </u>	A2	5,578,568	11/26/96	Ammons et al.	514	12	
	A3	5,576,292	11/19/96	Elsbach et al.	514	12	FSH.
	A4	5,532,216	07/02/96	Espevik et al.	514	21	MAR CEN
	A5	5,523,288	06/04/96	Cohen et al.	514	12	2 ;
	A6	5,494,896	02/27/96	Hansbrough, J.F.	514	12	1600/2900
	A7	5,488,034	01/30/96	McGregor et al.	514	12	290/290
	A8	5,484,705	01/16/96	White et al.	435	7.32	
	A9	5,466,581	11/14/95	White et al.	435	7.32	
	A10	5,466,580	11/14/95	White et al.	435	7.1	
	A11	5,447,913	09/05/95	Ammons et al.	514	12	
	A12	5,439,807	08/08/95	Grinna, L.S.	435	69.1	
	A13	5,420,019	05/30/95	Theofan et al.	435	69.1	
	A14	5,348,942	09/20/94	Little II, et al.	514	12	
	A15	5,334,584	08/02/94	Scott et al.	514	12	
	A16	5,308,834	05/03/94	Scott et al.	514	12	
	A17	5,245,013	09/14/93	Ulevitch et al.	530	380	
	A18	5,234,912	08/10/93	Marra et al.	514	21	
$\mathcal{J}$	A19	5,198,541	03/30/93	Elsbach et al.	435	69.1	
An	A20	5,171,739	12/15/92	Scott <i>et al</i> .	514	12	

EXAMINER <sub>2</sub>		DATE CONSIDERED	) ,
HSdel H.	1 Volamed	3/1	2/03
•			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IPE.	<u> </u>		SHEET	2 of	18
Form PTO-1449 (Modified)  MAR 2 1 2002	U.S. Department of Commerce Patent and Trademark Office	Atty: Docket No. 29715/35152R	Serial No. 09/991,603	TECH	
INFORMATION DISONOSUR	F STATEMENT	Applicant Giroir et al.		1 CENT	
(Use several sheets if necess		Filing Date November 23, 2001	Group 1654 /653	ER 160	i
				0	

	U.S. PATENT DOCUMENTS						
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Au	A21	5,089,274	02/18/92	Marra <i>et al</i> .	424	534	

FOREIGN PATENT DOCUMENTS								
							Translation	
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No
m	B1	WO 96/21436	07/18/96	PCT			100	
	B2	WO 96/08509	03/21/96	PCT			<u>i</u>	
	В3	WO 96/01647	01/25/96	PCT			N N	R 2
2.	B4	WO 95/24209	09/14/95	PCT				-! <b>v</b> 2 20 n do
	B5	WO 95/20163	07/27/95	PCT			7/00	2002/ 2002/
	В6	WO 95/19784	07/27/95	PCT			) POG	
	В7	WO 95/19372	07/20/95	PCT				
	В8	WO 95/19180	07/20/95	PCT			CHE C	· -
	В9	WO 95/19179	07/20/95	PCT				
	B10	WO 95/10297	04/20/95	РСТ				·
	B11	WO 95/08773	03/30/95	PCT				
	B12	WO 95/08344	03/30/95	PCT	6.2			F
	B13	WO 95/02414	01/26/95	PCT c				7 ==
	B14	WO 95/01428	01/12/95	PCT	<u> </u>			
AN	B15	WO 95/00641	01/05/95	PCT				

EXAMINER Abdel	A. Mohamed	DATE CONSIDERED 3/12/62
		' '

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1654/6

November 23, 2001

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS Translation Publication Subclass \*Examiner Document Country Class Yes No Initials Number Date **B16** WO 94/25476 11/10/94 **PCT B17** WO 94/21280 09/29/94 **PCT** WO 94/20532 09/15/94 **PCT B18 B19** WO 94/20129 09/15/94 **PCT B20** WO 94/20128 09/15/94 **PCT B21** WO 94/18323 08/18/94 **PCT** 08/18/94 WO 94/17819 **PCT B22 B23** WO 93/23540 11/25/93 **PCT B24** WO 93/06228 04/01/93 **PCT** B25 WO 93/05797 04/01/93 **PCT B26** WO 93/23434 11/25/93 **PCT B27 PCT** WO 92/09621 06/11/92 **B28** WO 92/03535 03/05/92 **PCT PCT B29** WO 91/01639 02/21/91

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
M	C1	Ammons et al., "Recombinant Amino Terminal Fragment of Bactericidal/ Permeability Increasing Protein Prevents Hemodynamic Responses to Endotoxin", Circulatory Shock. 41(3):176-184 (November, 1993).			

**PCT** 

08/23/90

EXAMINER Abdel A. Molaured

WO 90/09183

**B30** 

DATE CONSIDERED

3/12/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE		SHEET 4	4 of 18
Form PTO-1449 (Modified) MAR 2 1 2002 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603	TECH
INFORMATION DISCLOSURE STATEMENT	Applicant Giroir et al.		31M3C
(Use several sheets if necessary)	Filing Date November 23, 2001	Group 1654-/653	R 1600
			2900

		8
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	C2	Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Rodent Models of Gram-Negative Sepsis: Role of Bactericidal Properties," J. Infect. Dis., 170(6):1473-82 (December, 1994).
	C3	Ammons et al., "An N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein Protects against Hemodynamic and Metabolic Derangements in Rat Gram-Negative Sepsis," J. Endotoxin Res., 3(1):57-66 (1996).
	C4	Ammons et al., "Protective Effects of an N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Endotoxemia and Gram-Negative Sepsis," Novel Therapeutics Strategies in the Treatment of Sepsis, pp. 55-70 (1996).
	C5	Baggiolini <i>et al.</i> , "Neutrophil-activating Peptide-1/Interleukin 8, a Novel Cytokine That Activates Neutrophils", <i>J. Clin. Invest.</i> , 84:1045-1049 (October, 1989).
	C6	Barron, "Pathophysiology of Septic Shock and implications for Therapy," <i>Clinical Pharmacy</i> , 12(11):829-845 (November, 1993).
	C7	Berry, L.N., "Introduction" in <i>Handbook of Endotoxin, Volume 3, Cellular Biology of Endotoxin</i> , Berry, L.N., (Ed.), Elsevier, Amsterdam, New York, Oxford, pp. xvii-xxi, (1985).
	C8	Binnema et al., "Quantitation of Urokinase Antigen in Plasma and Culture Media by Use of an Elisa," <i>Thromb. Res, 43</i> :569-577 (1986).
	С9	Bloom <i>et al.</i> , "Serum Neopterin Levels Following Intravenous Endotoxin Administration to Normal Humans", <i>Immunobiol.</i> , 181:317-323 (1990).
	C10	Boermeester <i>et al.</i> , "Bactericidal/Permeability-Increasing Protein (BPI) Prevents Hemodynamic and Metabolic Derangements Following Partial Hepatectomy," Dutch Society of Gastroenterology Meeting, p. 84 (October 7, 1993) ( <i>ABSTRACT</i> ).
W.	C11	Boermeester et al., "A Prophylactic Approach towards Postoperative Endotoxemia," in Yearbook of Intensive Care and Emergency Medicine 1994, Vincent, J.L., (Ed.), Springer-Verlag, pp. 35-41 (1994).

EXAMINER ASSO	A. Mohamed	DATE CONSIDERED	3/12/03
		<u> </u>	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 5 of 18 Serial No. Form PTO-1449 (Modified) U S. Department of Commerce Atty. Docket No. Patent and Trademark Office 29715/35152R 09/991,603 Applicant Giroir et al. OSURE STATEMENT Filing Date Group 1654 November 23, 2001 (Use several sheets if necessary)

		290
	<b>T</b>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
pw	C12	Boermeester <i>et al.</i> "Endotoxin and Interleukin-1 Related Hepatic Inflammatory Response Promotes Liver Failure After Partial Hepatectomy," <i>Hepatology</i> , 22(5):1499-15006 (November, 1995).
<u> </u>	C13	Boermeester et al., "Liver Failure Induces a Systemic Inflammatory Response," Amer. J. Pathology, 147(5):1428-1440 (November, 1995)
:	C14	Bone, R.C., "The Pathogenesis of Sepsis," Ann. Inter. Med., 115:457-469 (1991).
	C15	Bone et al., "Definitions for sepsis and organ failure", Critical Care Medicine, 20(6):724-726 (1992).
	C16	Boujoukos et al., "Detection of Interleukin-8 in Bronchoalveolar Lavage Without Alveolar Neutrophil Influx, Before and After Intravenous Endotoxin in Normal Humans", Am. Rev. Resp. Dis., 145(4):A441 (April, 1992) (ABSTRACT).
,	C17	Boujoukos et al., "Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration", J. Appl. Physiol., 74:3027-3033 (1993).
	C18	Bradley et al., "Hemodynamic Alterations in Normotensive and Hypertensive Subjects During the Pyrogenic Reaction", J. Clin. Invest., 24:749-758 (1945).
	C19	Brandtzaeg et al., "Plasma Endotoxin as a Predictor of Multiple Organ Failure and Death in Systemic Meningococcal Disease," J. Infect. Dis., 159(2):195-204 (February, 1989).
	C20	Brandtzaeg et al., "Plasminogen Activator Inhibitor 1 and 2, Alpha-2-Antiplasmin, Plasminogen, and Endotaxin Levels in Systemic Meningococcal Disease," <i>Thrombosis Research</i> , 57:271-278 (1990).
	C21	Brandtzaeg <i>et al.</i> , "Meningococcal Endotoxin in Lethal Septic Shock Plasma Studied by Gas Chromatography, Mass-Spectrometry, Ultracentrifugation, and Electron Microscopy," <i>J. Clin. Invest.</i> , 89:816-823 (March, 1992).
	C22	Brandtzaeg, P., "Pathogenesis of Meningococcal Infections," in <i>Meningococcal Disease</i> , K. Cartwright, Ed., John Wiley & Sons, Ltd. pp. 72-114 (1995).
M	C23	Brigham et al., "Endotoxin and Lung Injury", Rev. Respir. Dis., 133:913-927 (1986).

EXAMINER Abdel A- Mohamed	DATE CONSIDERED	112/03
---------------------------	-----------------	--------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		(C)
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
My	C24	Calandra et al., "Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock", J. Infect. Diseases, 161:982-987 (May, 1990).
	C25	Calandra et al., "High Circulating Levels of Interleukin-6 in Patients with Septic Shock: Evolution During Sepsis, Prognostic Value, and Interplay with Other Cytokines", Am. J. Medicine, 91:23-29 (July, 1991).
	C26	Cannon et al., "Circulating Interleukin 1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever", J. Infect. Diseases, 161:79-84 (January, 1990).
	C27	Cavaillon, J.M., "Controversies Surrounding Current Therapies for Sepsis Syndrome," <i>Bull. Inst. Pasteur.</i> , 93:21-41 (1995).
	C28	Chmielewska et al., "Evidence For a Rapid Inhibitor To Tissue Plasminogen Activation in plasma," <i>Thromb. Res.</i> , 31:427-436 (1983).
	C29	Cochrane, "The Enhancement of Inflammatory Injury", Am. Rev. Respir. Dis., 136:1-2 (1980).
	C30	Colman, "Surface-mediated Defense Reactions, The Plasma Contact Activation System", J. Clin. Invest., 73:1249-1253 (May, 1984).
	C31	Cross et al., "Choice of Bacteria in Animal Models of Sepsis," Infect. Immun., 61(7):2741-2747 (July, 1993).
	C32	Cross, A.S., "Antiendotoxin Antibodies: A Dead End?" Ann. Intern. Med., 121(1):58-60 (July 1, 1994).
	C33	Danner et al., "Endotoxemia in Human Septic Shock", Chest, 99:169-175 (January 1991).
	C34	de Winter <i>et al.</i> , "Recombinant Endotoxin-Binding Protein (rBPI <sub>23</sub> ) Attenuates Endotoxin-Induced Circulatory Changes in Humans," <i>J. Inflamm.</i> , 45:193-206 (1995).
	C35	De La Cadena <i>et al.</i> , "Activation of the Kallikrein-Kinin System After Endotoxin Administration to Normal Human Volunteers", <i>Blood</i> , 81(12):3313-3317 (June 15, 1993).

Model A- Mohamed 5/12/6	EXAMINER DATE CONSIDERED 2 32
-------------------------	-------------------------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) MAR 2 1 2002 INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

Applicant

Giroir et al.

Filing Date

November 23, 2001

Group 1654-(6)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
m	C36	Dinarello, C.A., "The Proinflammatory Cytokines Interleukin-l and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome", <i>J. Infection Diseases</i> , 163:1177-1184 (June, 1991).
	C37	Edwards et al., "Complications and Sequelae of Meningococcal Infections in Children," J. of Pediatrics, 99(4):540-545 (October, 1981).
	C38	Elin et al., "Effect of Induced Fever on Serum Iron and Ferritin Concentrations in Man", Blood, 49(1):147-153 (January, 1977).
	C39	Elms et al., "Measurement of Crosslinked Fibrin Degradation Products-An Immunoassay Using Monoclonal Antibodies," <i>Thromb. Haemostas</i> , 50(2):591-594 (1983).
	C40	Elsbach <i>et al.</i> , "Separation and Purification of a Potent Bactericidal/Permeability Increasing Protein and a Closely Associated Phospholipase A <sub>2</sub> from Rabbit Polymorphonuclear Leukocytes," <i>J. Biol. Chem.</i> , 254(21):11000-11009 (November, 1979).
	C41	Elsbach and Weiss, "Oxygen-Independent Antimicrobial Systems of Phagocytes," In <i>Inflammation: Basic Principles and Clinical Correlates</i> , Chapter 30, Second Edition, Gallin <i>et al.</i> , ( <i>Eds.</i> ), Raven Press, Ltd., pp. 603-636, (1992).
	C42	Elsbach et al., "Prospects for Use of Recombinant BPI in the Treatment of Gram-Negative Bacterial Infections," Infect. Agents Dis., 4:102-109 (1995).
	C43	Evans et al., "Protective Effects of a Recombinant Amino-Terminal Fragment of Human Bactericidal/Permeability-Increasing Protein in an Animal Model of Gram-Negative Sepsis," J. Infect. Dis., 171:153-60 (January, 1995).
	C44	Fijnvandraat <i>et al.</i> , "Endotoxin Induced Coagulation Activation and Protein C Reduction in Meningococcal Septic Shock," in <i>Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies</i> , Wiley-Liss, Inc., pp. 247-254 (1994).
WW	C45	Fink, M.P., "Adoptive Immunotherapy of Gram-Negative Sepsis: Use of Monoclonal Antibodies to Lipopolysaccharide," <i>Crit. Care.Med. (Supplement)</i> , 21(2):S32-S39 (February, 1993).

1+5del A. Mohamed   3/12/03	EXAMINER Holel A. Mohamed	DATE CONSIDERED	1/2	103
-----------------------------	---------------------------	-----------------	-----	-----

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 29715/35152R Serial No. 09/991,603

Applicant Giroir et al.

Filing Date

November 23, 2001

Group

1654

INFORMATION ELSCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Fiser, "Assessing the Outcome of Pediatric Intensive Care," J. Pediatrics, 121:168-C46 174 (1992). Fisher et al., "Human neutrophil bactericidal/permeability-increasing protein C47 reduces mortality rate from endotoxin challenge: A placebo-controlled study," Crit. Care Med., 22(4):553-558 (April, 1994). C48 Fisher et al., "Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results form a Randomized, Doubleblind, Placebo-Controlled Trial, " JAMA, 271 (23):1836-1878 (June 15, 1994). Flaegstad et al., "Factors associated with fatal outcome in childhood meningococcal C49 disease," Acta Paediatr., 84:1137-1142 (1995). Fong et al., "Endotoxemia Elicits Increased Circulating β2-IFN/IL-6 in Man", J. C50 Immunology, 142(7):2321-2324 (April 1, 1989). Fong et al., "Total Parental Nutrition and Bowel Rest Modify the Metabolic C51 Response to Endotoxin in Humans", Ann. Surg., 210(4):449-457 (October, 1989). C52 Fong et al., "The Acute Splanchnic and Peripheral Tissue Metabolic Response to Endotoxin in Humans", J. Clin. Invest., 85:1896-1904 (June, 1990). C53 Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," Infect. Immun., 60(11):4754-4761 (November, 1992). C54 Genoff et al., "Extremity Amputations in Meningococcemia-Induced Purpura Fulminans," Plastic Reconstructive Surg., 89(5):878-881 (May, 1992). Giroir et al., "Meningococcemia," in Essentials of Pediatric Intensive Care, Second C55 Edition, Volume One, Levin D.L. and Morriss, F.C., Eds., Quality Medical Publishing, Inc., pp. 421-427 (1997) C56 Giroir et al., "Shock," in Essentials of Pediatric Intensive Care, Second Edition, Volume One, Levin D.L. and Morriss, F.C., Eds., Quality Medical Publishing, Inc., pp. 280-301 (1997).

				<del></del>	1 1
EXAMINER AL del	A.	Mohame d	DATE CONSIDERED	3	12/03
<del></del>			<del></del>		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) INFORMATION DIS **ÜRE STATEMENT** 

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

Applicant

Giroir et al.

Filing Date November 23, 2001 Group

1654/613

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	C57	Granowitz <i>et al.</i> , "Production of interleukin-1-receptor antagonist during experimental endotoxaemia", <i>Lancet</i> , <i>338</i> :1423-24 (December 7, 1991).
	C58	Granowitz <i>et al.</i> , "Hematologic and Immunomodulatory Effects of an Interleukin-1 Receptor Antagonist Coinfusion During Low-Dose Endotoxemia in Healthy Humans", <i>Blood</i> , <i>82(10):</i> 2985-2990 (November 15, 1993).
	C59	Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," J. Biol. Chem., 264(16):9505-9509 (June 5, 1939).
	C60	Hack et al., "A Modified Competitive Inhibition Radioimmunoassay for the Detection of C3a Use of <sup>125</sup> I-C3 Instead of <sup>125</sup> I-C3a", <i>J. Immunol. Meth.</i> , 108:77-84 (1988).
	C61	Halstensen et al., "Sequelae One Year After Meningococcal Disease," Acta. Neurol. Scand., 89:139-142 (1994).
	C62	Havens et al., "Trends in Mortality in Children Hospitalized With Meningococcal Infections, 1957-1987," Pediatr. Infect. Dis. J., 8(1):8-11 (1988).
	C63	Hesse et al., "Cytokine Appearance in Human Endotoxemia and Primate Bacteremia", Surg., Gyn. & Obstet., 166:147-153 (February, 1988).
	C64	Hochberg, Y., "A sharper Bonferroni procedure for multiple tests of significance," Biometrika, 75(4):800-802 (1988).
	C65	Hoffman et al., "Endotoxin in Septic Shock," Anesth. Analg., 77:613-624 (1993).
	C66	Holvoet, P. et al., "Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA," <i>Thromb. Haemastasis.</i> , 54(3):684-687 (1985).
	C67	In't Veld., "Effects of the Bactericidal/Permeability-Increasing Protein of Polymorphonuclear Leukocytes on Isolated Bacterial Cytoplasmic Membrane Vesicles", <i>Infect. Immun.</i> , 56(5):1203-1208 (May, 1988).
Em.	C68	Kelly et al., "Role of the bactericidal permeability-increasing protein in the treatment if gram-negative pneumonia", Surgery, 114(2):140-146 (August, 1993).

EXAMINER Abdel A. Wohamed	DATE CONSIDERED	12/03
---------------------------	-----------------	-------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SHEET 10 of 18** Atty. Docket No. Serial No. Form PTO-1449 (Modified) U.S. Department of Commerce MAR 2 1 2002 Patent and Trademark Office 29715/35152R 09/991,603 Applicant INFORMATION DISCLESSURE STATEMENT Giroir et al. Group 1654 /653 Filing Date November 23, 2001 (Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
m	C69	Kindt et al, "Initial recruitment of neutrophils to alveolar structures in acute lung injury", J. Appl. Physiol., 70:1575-1585 (1991).
<u></u>	C70	Kirsch, E. <i>et al.</i> , "Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience," <i>Pediatr Infect Dis J.</i> , <i>15(11)</i> :967-979 (1996).
	C71	Koch, G.G., "The Use of Non-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over Design," <i>Biometric</i> , 28:577-584 (1972).
	C72	Kohn et al., "Protective Effect of a Recombinant Amino-Terminal Fragment of Bactericidal/Permeability-Increasing Protein in Experimental Endotoxemia", J. Infect. Diseases, 168:1307-1310 (November, 1993).
	C73	Kohn et al., "Role of Endotoxin in Acute Inflammation Induced by Gram-Negative Bacteria: Specific Inhibition of Lipopolysaccharide-Mediated Responses with an Amino-Terminal Fragment of Bactericidal/Permeability-Increasing Protein." Infect. Immun., 63(1):333-339 (January, 1995).
	C74	Koyama et al., "rBPI <sub>23</sub> Attenuates Endotoxin-Induced Cardiovascular Depression in Awake Rabbits," SHOCK, 4(1):74-78 (July, 1995).
	C75	Kung et al., "Efficacy of a recombinant terminal amino fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria," In Bacterial Endotoxins: Basic Science to Anti-Sepsis Strategies, Wiley-Liss, Inc., New York, pp. 255-263 (1994).
	C76	Kung et al., "Pharmacokinetic Evaluations of rBPI <sub>23</sub> in Mice, Rats, and Humans," International Conference on Endotoxemia IV, Amsterdam, The Netherlands, p. 23, (August 17-29, 1993) (ABSTRACT P3).
	C77	Leach et al., "Prevention of Lethal Endotoxemia by BP <sub>23</sub> ", J. Cell. Chem, (Keystone Symposia, Suppl.) 16(C):172 (February 21 - March 7, 1992) (ABSTRACT CB 412).
2	C78	Lechner <i>et al.</i> , "The Recombinant 23-kDa N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein (rBPI <sub>23</sub> ) Decreases <i>Escherichia Coli</i> -Induced Mortality and Organ Injury During Immunosuppression-Related Neutropenia," <i>SHOCK</i> , 4(4):298-306 (October, 1995).

EXAMINER Abdel A Molicine d DATE CONSIDERED	3/12/03
---	---------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)



U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R

November 23, 2001

Serial No. 09/991,603

Applicant

Filing Date

Giroir et al.

Group

1654 413

## INFORMATION DISCUSSURE STATEMENT

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
Au	C79	Levi et al., "Reduction of Contact Activation Related Fibrinolytic Activity in Factor XII Deficient Patients," J. Clin. Invest., 88:1155-1160 (October, 1991).				
	C80	Levy et al., "Antibacterial 15-kDa Protein Isoforms (p15s) Are Members of a Novel Family of Leukocyte Proteins", J. Biol. Chem., 268(8):6058-6063 (March, 1993).				
	C81	Lichtman <i>et al.</i> , "Reactivation of Arthritis Induced by Small Bowel Bacterial Overgrowth in Rats: Role of Cytokines, Bacteria, and Bacterial Polymers," <i>Infect. Immun.</i> , 63(6):2295-2301 (June, 1995).				
	C82	Lin et al., "Protective Effect Of A Recombinant Fragment Of Bactericidal/Permeability Increasing Protein Against Carbohydrate Dyshomeostasis And Tumor Necrosis Factor-α Elevation In Rate Endotoxemia," Biochem. Pharmacol. 47(9):1553-1559 (1994).				
	C83	Lin et al., "Protective Effects of a Recombinant N-Terminal Fragment of Bactericidal/Permeability Increasing Protein on Endotoxic Shock in Conscious Rabbits," SHOCK, 2(5):324-331 (November, 1994).				
	€84	Lin et al., "Synergistic Effect of a Recombinant N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein and Cefamandole in Treatment of Rabbit Gram-Negative Sepsis," Antimicrobial Agents and Chemotherapy, 40(1):65-69 (January, 1996).				
	C85	MacIntyre et al., "E5 Antibody Improves Outcome from Multi-Organ Failure in Survivors of Gram-Negative Sepsis", Critical Care Medicine, S14 (April, 1991).				
	C86	Mannion et al., "Separation of Sublethal and Lethal Effects of Polymorphonuclear Leukocytes on Escherichia coli", J. Clin. Invest., 86:631-641 (August 1990).				
	C87	Marra et al., "Bactericidal/Permeability-Increasing Protein Has Endotoxin-Neutralizing Activity", J. Immunol, 144(2):662-666 (January 15, 1990).				
W.	C88	Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", J. Immunol., 148(2):532-537 (January 15, 1992).				

EXAMINER Abdel	A. Molamal	DATE CONSIDERED	3	12/03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

**Applicant** 

Giroir et al.

Group

(Use several sheets if necessary)

Filing Date November 23, 2001 1654

		<u>'ÿ</u>
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
My	C89	Marra et al., "Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5," Crit. Care. Med., 22(4):559-565 (1994).
	C90	Martich et al., "Detection of Interleukin 8 and Tumor Necrosis Factor in Normal Humans after Intravenous Endotoxin: The Effect of Antiinflammatory Agents", J. Exp. Medicine, 173:1021-1024 (April, 1991).
	C91	Martich <i>et al.</i> , "Effects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin", <i>J. Appl. Physiol.</i> , 73(3):925-931 (1992).
	C92	Martich et al., "Intravenous Endotoxin Administration to Normal Humans Primes Neutrophils for an Enhanced Respiratory Burst", Critical Care Medicine, S100 (April, 1992).
	C93	Martich et al., "Response of Man to Endotoxin", Immunobiol., 187(3-5):403-416 (April, 1993).
	C94	McManus et al., "Coagulopathy as a Predictor of Outcome in Meningococcal Sepsis and the Systemic Inflammatory Response Syndrome With Purpura," Critical Care Medicine, 21(5):706-711 (1993).
	C95	Meszaros et al., "A Recombinant Amino Terminal Fragment of Bactericidal/Permeability-Increasing Protein Inhibits the Induction of Leukocyte Responses by LPS," <i>J. Leukocyte Biol.</i> , 54(6):558-563 (December, 1993).
	C96	Meszaros et al., "Monocyte Tissue Factor Induction by Lipopolysaccharide (LPS): Dependence on LPS-Binding Protein and CD14, and Inhibition by a Recombinant Fragment of Bactericidal/Permeability-Increasing Protein," Blood, 83(9):2516-2525 (May 1, 1994).
	C97	Michie et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration", N. Eng. J. Medicine, 318(23):1481-1486 (June 9, 1988).
	C98	Moore et al., "A Single Dose of Endotoxin Activates Neutrophils without Activating Complement", Surgery, 102(2):200-205 (August, 1987).
M	C99	Moser et al., "Cardiopulmonary Consequences of Pyrogen-Induced Hyperpyrexia in Man", J. Clin. Invest., 42(5):626-634 (1963).

EXAMINER	A6des	) A.	Mohamo d	DATE CONSIDERED	3	12/03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) MAR 2 1 2002 INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

Applicant

Giroir et al.

Filing Date November 23, 2001 1654/653

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
m	C100	Nadel et al., "Treatment of Meningococcal Disease in Childhood," in Meningococcal Disease, Cartwright, ed., J. Wiley & Sons, New York, pp. 207-243 (1995).			
	C101	Natanson <i>et al.</i> , "Role of Endotoxemia in Cardiovascular Dysfunction and Mortality", <i>J. Clin. Invest.</i> , 83:243-251 (January, 1989).			
	C102	Natanson <i>et al.</i> , "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis," <i>Ann. Inter. Med.</i> , 120(9):771-783 (May 1, 1994).			
	C103	Niklasson et al., "Prognostic Factors in Meningococcal Disease," Scand. J. Infect. Dis., 3:17-25 (1971).			
	C104	Nuijens et al., "Plasma Elastase $\alpha_1$ -antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators in fatal sepsis", J. Lab. Clin. Med., 119:159-168 (1992).			
	C105	Ooi et al., "A 25-kDa NH <sub>2</sub> -terminal Fragment Carries Ail the Antibacterial Activities of the Human Neutrophil 60-kDa Bactericidal/Permeability-increasing Protein," J. Biol. Chem., 262(31):14891-14894 (1987).			
	C106	Ooi et al., "Isolation of Two Isoforms of a Novel 15-kDa Protein from Rabbit Polymorphonuclear Leukocytes That Modulate the Antibacterial Actions of Other Leukocyte Proteins," J. Biol. Chem., 265:15956-15962 (September 15, 1990).			
	C107	Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 KDC-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," J. Exp. Med., 174:649-655 (September, 1991).			
	C108	Parker et al., "Profound but Reversible Myocardial Depression in Patients with Septic Shock," Ann. Intern. Med., 100:483-490 (1984).			
	C109	Parker <i>et al.</i> , "Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis," <i>J. Crit. Care.</i> , 15(10):923-929 (1987).			
Zv.	C110	Parrillo et al., "Septic Shock in Humans", Annals of Int. Med. 113(3):227-242 (August, 1990).			

EXAMINER Abdil	A. Wohamed	DATE CONSIDERED	3/12/	03
----------------	------------	-----------------	-------	----

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) MAR 2 1 2002 INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R Serial No. 09/991,603

Applicant

Giroir et al.

Filing Date

Group November 23, 2001

<u> 1654 /</u>653

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
m	C111	Peters et al., "Rapid Microanalysis of Coagulation Parameters by Automated Chromogenic Substrated Methods-Application in Neonatal Patients," <i>Thromb. Res.</i> , 28:773-781 (1982).			
	C112	Petros et al., "Effects of a Nitric Oxide Synthase Inhibitor in Humans With Septic Shock," Cardiovascular Research, 28:34-39 (1994).			
	C113	Pollack et al., "Pediatric Risk of Mortality (PRISM) Score," Critical Care Medicine, 16(11):1110-1116 (November, 1988).			
	C114	Powars et al., "Epidemic Meningococcemia and Purpura Fulminans with Induced Protein C Deficiency," Clinical Infectious Diseases, 17:254-261 (1993).			
	C115	Pruzanski et al., "Hyperphospholipasemia $A_2$ in Human Volunteers Challenged with Intravenous Endotoxin", <i>Inflammation</i> 16(5):561-570 (1992).			
	C116	Quezado et al., "A Controlled Trial of HA-1A in a Canine Model of Gram-negative Septic Shock," JAMA. 269(17):2221-2227 (May 5, 1993).			
	C117	Quezado et al., "New Strategies for Combating Sepsis: The Magic Bullets Missed the MarkBut the Search Continues." <i>TibTech</i> , 13:56-63 (February, 1995).			
	C118	Rackow <i>et al.</i> , "Hemodynamic Response to Fluid Repletion in Patients With Septic Shock: Evidence for Early Depression of Cardiac Performance," <i>Circ. Shock, 22</i> :11-22 (1987).			
	C119	Revhaug et al., "Inhibition of Cyclo-oxygenase Attenuates the Metabolic Response to Endotoxin in Humans", Arch. Surg. 123:162-170 (February, 1988).			
	C120	Scannon, P.J., "Applying Lessons Learned from Anti-Endotoxin Therapy," <i>J. Endo. Res.</i> , 2:217-220 (1995).			
	C121	Schlag <i>et al.</i> , "Protective Effect of Bactericidal/Permeability Increasing Protein (rBPI <sub>21</sub> ) on Sepsis Induced Organ Failure in Nonhuman Primates," <i>SHOCK Conference</i> , Ashville, N.C. June 11-14, (1995) ( <i>ABSTRACT</i> ).			
- AM	C122	Sheridan et al., "Management Strategy in Purpura Fulminans with Multiple Organ Failure in Children," Burns. 22(1):53-56 (1996).			

175del 4). Molimed 3/1403		03
---------------------------	--	----

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) INFORMATION DISCESSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 29715/35152R

Serial No. 09/991,603

Applicant

Giroir et al.

Filing Date November 23, 2001 Group

1654 / 65

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
M	C123	Sinclair et al., "Prognosis of Meningococcal Septicaemia," Lancet, 2:38 (July 4, 1987).			
	C124	Smith et al., "Endotoxin Administration to Normal Humans Causes Increased Alveolar Permeability and Priming of Alveolar Macrophages to Produce Enhanced Superoxide and IL-1 Production", Clin. Res. 36:374A (April, 1988) (ABSTRACT).			
	C125	Spinas <i>et al</i> , "Induction of plasma inhibitors of interleukin 1 and TNF-α activity by endotoxin administration to normal humans", <i>Am. J. Physiol.</i> , 259:R933-R997 (1990).			
	C126	Spinas <i>et al.</i> , "Pretreatment with Ibuprofen Augments Circulating Tumor Necrosis Factor-α, Interleukin-6, and Elastase during Acute Endotoxinemia", <i>J. Infectious Dis.</i> , 163:89-85 (1991).			
	C127	Steven et al., "The Clinical Spectrum of Meningococcal Disease," in Meningococcal Disease, Cartwright, ed., J. Wiley & Sons, New York, pp. 178-205 (1995).			
	C128	Stiehm & Damrosch, "Factors in the prognosis of meningococcal infection," <i>J. Pediatrics</i> , 68:457-467 (1966).			
	C129	Sturk et al., "Optimalization of a Chromogenic Assay for Endotoxin in Blood," in Bacterial Endotoxins: Structure, Biomedical Significance, and Detection with the Limulus Amebocyte Lysate Test, pp. 117-136 (1985).			
	C130	Suffredini et al., "Promotion and Subsequent Inhibition of Plasminogen Activation after Administration of Intravenous Endotoxin to Normal Subjects", N. Eng. J. Medicine, 320(18):1165-1172 (May 4, 1989).			
	C131	Suffredini et al., "The Cardiovascular Response of Normal Humans to the Administration of Endotoxin", N. Eng. J. Medicine, 321:280-287 (August 3, 1989).			
	C132	Suffredini <i>et al.</i> , "Pulmonary and Oxygen Transport Effects of Intravenously Administered Endotoxin in Normal Humans", <i>Am. Rev. Respir. Dis.</i> , 145:1398-1403 (1992).			
l m	C133	Suffredini, A.F., "Current Prospects for the Treatment of Clinical Sepsis," <i>Crit. Care Med.</i> , 22(7):S12-S18 (July, 1994).			

EXAMINER Abdel	A. Moha	rine or	DATE CONSIDERED	3/17/03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) MAR 2 1 2002

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. Serial No. 29715/35152R 09/991,603

Applicant Giroir *et al*.

Filing Date G

November 23, 2001

Group 1654 / 6 / 35

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author Title Date Pertinent Pages etc.)
	<b>,</b>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
M	C134	Teitel <i>et al.</i> , "Studies of the Prothrombin Activation Pathway Utilizing Radioimmunoassays for the $F_2/F_{1+2}$ Fragment and Thrombin-Antithrombin Complex," <i>Blood</i> , 59(5):1086-1096 (May, 1982).
	C135	Tesoro et al., "Factors Affecting Outcome in Meningococcal Infections," AJDC, 145:218-220 (February, 1991).
	C136	Thornton et al., "Bactericidal/Permeability-Increasing Protein Inhibits Tumor Necrosis Factor Release in Whole Blood in Response to Neisseria Meningitidis and N. Gonorrhoeae," FASEB J., 8(4):A137 (1994) (ABSTRACT 794).
	C137	van Deventer et al., "Experimental Endotoxemia in Humans: Analysis of Cytokine Release and Coagulation, Fibrinolytic, and Complement Pathways', Blood. 76(12):2520-2526 (December 15, 1990).
	C138	Van Dueren et al., "Correlation between Proinflammatory Cytokines and Antiinflammatory Mediators and the Severny of Disease in Meningococcal Infections," J. Infect. Dis., 172:433-439 (1995).
	C139	van Leeuwan et al., "Hepatic Failure and Coma After Liver Resection is Reversed by Manipulation of Gut Contents. The Role of Endotoxin," Surgery, 110(2):169-175 (August, 1991).
	C140	Van Zee <i>et al.</i> , "Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor, α <i>in vitro</i> and <i>in vivo</i> ", <i>Proc. Natl. Acad. Sci. USA.</i> , 89:4845-4849 (June, 1992).
	C141	Van Zee <i>et al.</i> , "Tumor Necrosis Factor (TNF) Soluble Receptors Protect Against Excessive TNFα During Infection and Injury", <i>Fed. Amer. Soc. Exp. Biol.</i> , 6:A1715 (1992) ( <i>ABSTRACT 4512</i> ).
	C142	VanderMeer et al., "Bactericidal/Permeability-Increasing Protein Ameliorates Acute Lung Injury in Porcine Endotoxemia," J. Infect. Dis., 172(1):2006-14 (May 1994)
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	C143	Verheijen et al., "A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma," Thromb. Haemostas. 48(3):266-269 (1982).

EXAMINER Abdel A. Molamod

DATE CONSIDERED

3/17/03


<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIFE		SHEEL 17 OF 18
Form PTO-1449 (Modified)  MAR 2 1 2002  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 29715/35152R	Serial No. 09/991,603
INFORMATION DESCRIPTION DESCRIPTION DESCRIPTION DESCRIPTION DE STATEMENT	Applicant Giroir et al.	MAR OER
(Use several sheets if necessary)	Filing Date November 23, 2001	Group 1654 (6051 N

, <del></del>		29
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
MM	C144	von der Möhlen <i>et al.</i> , "Effect of rBPI <sub>23</sub> on Endotoxin-induced Cytokine Release and Leukocyte Changes in Human Volunteers" <i>Clinical Research</i> , 42(2):152A (April, 1994) ( <i>ABSTRACT</i> ).
,	C145	Waage et al., "The Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock", J. Exp. Med. 169:333-338 (January, 1989).
	C146	Weiss et al., "Resistance of Gram-negative Bacteria to Purified Leukocyte Proteins", J. Clin. Invest., 65:619-628 (March, 1980).
	C147	Weiss et al., "The Role of Lipopolysaccharide in the Action of the Bactericidal/Permeability Neutrophil Protein on the Bacterial Envelope", J. Immunol., 132:3109-3115 (June, 1984).
	C148	Weiss et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," Blood, 69(2):652-659 (February, 1987).
	C149	Weiss et al., "Tissue Destruction by Neutrophils", N. Eng. J. Medicine, 320(6):365-376 (February 9, 1989).
	C150	Weiss et al., "Human Bacterial/Permeability-Increasing Protein and a Recombinant NH <sub>2</sub> -Terminal Fragment Cause Killing of Serum-resistant Gram-negative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria," J. Clin. Invest., 90:1122-1130 (September, 1992).
	C151	Wolff, "Biological Effects of Bacterial Endotoxins in Man", J. Infectious Diseases 128(Supplement):S259-S264 (July, 1973).
	C152	Wong et al., "Meningococcal Infections in Children: As Review of 100 Cases," Pediatr. Infect. Dis. J., 8(4):224-227 (1989).
	C153	Yao et al., "Pathogenesis of Hemorrhage-Induced Bacteria/Endotoxin Translocation in Rats," Annals Surg., 221(4):398-405 (April, 1995).
	C154	Yong et al., "An Experiment Mouse Model of Yersinia-induced Reactive Arthritis," <i>Microbial Path.</i> , 4:305-310 (1988).
gn	C155	Yong et al., "Protective Effect of Re-LPS Antiserum on Experimental Multiple System Organ Failure," Chinese Medical Journal, 105(10):833-838 (October, 1992).

EXAMINER	Abdel A	1. Molime d	DATE CONSIDERED	3/12/03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
M	C156	C156 Zabel <i>et al.</i> , "Oxpentifylline in Endotoxaemia", <i>Lancet. 2:</i> 1474-1477 (December 23/30, 1989).		
	C157	Kartalija et al., "Effect of Recombinant N-Terminal Fragment of Bactericidal/Permeability-Increasing Protein (rBPI-23) on Cerebrospinal Fluid Inflammation Induced by Endotoxin," <i>J. Infectious Diseases</i> , 171(4):948-953 (April, 1995).		
	C158	Kirch et al., "Phase I/II Trial of rBPI-21 (A Recombinant 21kD Fragment of Bactericidal/Permeability-Increasing Protein) in Children With Severe Meningococcemia," Pediatric Research, 41(4):35A (April, 1997).		
	C159 ·	Thornton et al., The FASEB Journal, Volume 8, No. 4, March 15, 1994, Abstract No. 794, page A137.		
	C160	Marijke <i>et al.</i> , Blood, Volume 35, No. 2, pp. 3437-3443, https://doi.org/10.1009/10.1		
pn	C161	Marijke et al., The Journal of Infectious Diseases, Volume 172, pp. 144-151, July 1995.		

EXAMINER 126	A. Molamed
--------------	------------

DATE CONSIDERED